{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.100","upperLimit":"24.000","value":"16.30"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"}],"units":"Participants"}],"description":"PFS was defined as the time from the first dose of study treatment to progressive disease (PD) or death due to any cause on study or within 28 days after study discontinuation, whichever occurred earlier.","dispersionType":"95% Confidence Interval","groups":[{"description":"Lenalidomide 25 mg administered orally once daily (QD) until progressive disease or unacceptable toxicity","id":"OG000","title":"Lenalidomide"}],"paramType":"MEDIAN","populationDescription":"The EE population consisted of all participants who met basic protocol requirements (all eligibility criteria) and were evaluated after receiving at least one dose of lenalidomide","reportingStatus":"POSTED","timeFrame":"From day 1 of study treatment to the date of disease progression; up to data cut date of date of 19 May 2017; maximum study duration was 134.1 weeks","title":"Kaplan Meier Estimate of Progression Free Survival (PFS) as Assessed by the ESEC","type":"SECONDARY","unitOfMeasure":"weeks"}